Background: Short-duration studies show that salsalate improves glycemia in type 2 diabetes mellitus (T2DM). Objective: To assess 1-year efficacy and safety of salsalate in T2DM. Design: Placebo-controlled, parallel trial; computerized randomization and centralized allocation, with patients, providers, and researchers blinded to assignment. (ClinicalTrials.gov: NCT00799643) Setting: 3 private practices and 18 academic centers in the United States. Patients: Persons aged 18 to 75 years with fasting glucose levels of 12.5 mmol/L or less (�225 mg/dL) and hemoglobin A 1c (HbA 1c) levels of 7.0 % to 9.5 % who were treated for diabetes. Intervention: 286 participants were randomly assigned (between January 2009 and July 2011) to 48 weeks of placebo (n � 140) or salsalate, 3.5 g/d (n � 146), in addition to current therapies, and 283 participants were analyzed (placebo, n � 137; salsalate, n
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.